

Relation of Blood Thromboplastin Activity to Its Total Phospholipid Content.* (27258)

HERSCHEL P. BENTLEY, JR.[†] AND WILLIAM KRIVIT (Introduced by Kendrick Hare)

*Department of Pediatrics, University of Alabama Medical Center, Birmingham,
and Department of Pediatrics, University of Minnesota, Minneapolis*

The important role of phospholipids in the clotting mechanism has been appreciated for many years. Various phospholipids have been investigated for their thromboplastic activity or for their ability to enhance coagulation(1-9). It now seems apparent that the ability of various phospholipids to support coagulation *in vitro* depends on their ability to form a colloidal suspension which, in turn, is influenced by the unsaturation of the fatty acids on the α' and β side chains(6), by pH, oxidation, ionic strength and temperature(4).

Our data relate the phospholipid content of blood thromboplastin to its thromboplastic activity.

Methods and materials. Blood from normal fasting human subjects was collected with siliconized equipment. A 20 ml sample was distributed among 3 tubes; 5 ml for oxalated plasma, 10 ml mixed with EDTA and 5 ml without anticoagulant for serum.

Blood thromboplastin was prepared from human blood by the method of Spaet and Cintron(10). Plasma and serum were separated and frozen at -20°C for use the next day. Dilutions of the thromboplastin reagents were made with 0.85% saline buffered to pH 7.3 with imidazole buffer. Platelets were obtained by differential centrifugation of blood containing EDTA, washed 3 times with 0.85% saline, and concentrated 3-fold in buffered saline. They were frozen at -20°C for use the next day. One ml of barium sulfate adsorbed human plasma diluted 1:5, one ml of serum diluted 1:10 and one ml of 0.025 M calcium chloride were placed in each of 3 glass centrifuge tubes. These were mixed by tilting and allowed to incubate for 15 minutes in a water bath at 37°C . At

this time, a filmy clot was usually present and was removed with a wooden applicator stick. Occasionally, an additional 5 minutes of incubation was necessary for clot formation to occur. One ml of the platelet suspension then was added to each tube and the mixture incubated for 5 minutes. The thromboplastic activity thus generated was checked by adding 0.1 ml of the mixture to recalcified human plasma and obtaining a clotting time. The tubes containing the thromboplastin mixture were centrifuged at 4°C at 18,500 rpm for 30 minutes. The supernatant was discarded, and the button of thromboplastin was suspended in 4 ml of buffered saline containing 0.025 M calcium chloride by grinding with a glass stirring rod. The tubes were centrifuged as before and the washing process repeated one additional time. After the final centrifugation, the buttons of thromboplastin were each resuspended in one ml of buffered saline-calcium chloride solution and pooled to give a total volume of 3 ml. The thromboplastic activity of these pooled thromboplastin suspensions was checked as previously described. A normal activity, measured by adding the thromboplastin to a substrate of recalcified human plasma, was denoted by a clotting time of 10-13.9 seconds. During the washing procedure thromboplastic activity very frequently was lost. That is, before centrifugation a good activity was obtained, but after repeated centrifugation and washing, final thromboplastic activity was markedly reduced. In other procedures formation of thromboplastin was inhibited by reducing the pH of the buffering saline to 4.5 and 3.0.

Three ml of this thromboplastin was analyzed in duplicate for total phospholipid content by the method of Marinetti(11,12) in 54 patients. In control procedures phospholipid content of whole plasma was measured after diluting it 1:2, 1:4 and 1:10 prior to analysis. The phospholipid content showed a linear de-

* Supported by U.S.P.H.S. grants.

[†] Part of the work was performed while a research fellow in the Dept. of Pediatrics, University of Minnesota.

On analyzing this observation of decreasing thromboplastin activity with decreasing phospholipid content, it seems evident that there are 2 distinct possible causes. One is that the increased activity and phospholipid content are directly related to a higher phospholipid content of the precursor ingredients




Table I shows the results obtained when total phospholipid content of the preincubation mixture is compared with total phospholipid found in the thromboplastin. The average of total lipid phosphorus in the preincubation mixtures associated with normal thromboplastic activity was 113.8 $\mu\text{g}\%$ and 106 $\mu\text{g}\%$ in those associated with abnormal thromboplastic activity. Yet the average in the thromboplastins with normal activity was 41.1 $\mu\text{g}\%$ and only 22.8 $\mu\text{g}\%$ in the abnormal. Essentially the same results are obtained when centrifugation of the precursor substances is carried out (Table II). Data

in both tables demonstrate that total phospholipid content of the precursor substances does not correlate at all with phospholipid content of the blood thromboplastin.

The higher yield of phospholipid found in active thromboplastins suggests that a loss of activity is coincident with a loss of phospholipid. However, as shown in Table III.

TABLE I. Lipid Phosphorus in Precursors and Thromboplastin as Related to Thromboplastin Activity.

	Final throm- boplastin ac- tivity in sec.	μg of lipid phosphorus	
		Preincuba- tion mixture	3 ml throm- boplastin
Normal activity	9.6	132	24
	10.0	126	69
	10.4	132	65
	10.6	100	70
	11.4	104	45
	11.6	80	39
	11.6	124	30
	11.6	80	40
	12.0	120	39
	12.2	108	33
	12.0	92	18
	12.6	92	25
	13.0	148	44
	13.2	156	35
Avg		113.8	41.4
Abnormal activity	14.0	124	40
	14.0	96	30
	14.0	92	20
	14.2	168	44
	14.6	132	56
	14.8	88	11
	16.2	156	17
	18.0	104	18
	19.4	96	17
	19.6	92	17
	19.8	100	15
	22.4	91	16
	25.8	86	23
	26.0	104	18
	27.0	80	16
	27.4	100	17
	34.6	92	14
Avg		106	22.8

a high yield of total phospholipid is obtained in samples in which thromboplastin formation was inhibited by lowering the pH. This strongly suggests that the mere presence of phospholipid is not sufficient for thromboplastic activity but that a definite pattern of coupling or certain essential phospholipids must be present to contribute significantly to the thromboplastic activity.

Discussion. Data similar to those pre-

TABLE II. Lipid Phosphorus in Centrifuged Precursor Substances and Thromboplastin as Related to Thromboplastin Activity.

	Final throm- boplastin ac- tivity in sec.	μg of lipid phosphorus	
		Precursor substance	2 ml throm- boplastin
Normal activity	7.2	120	95
	7.2	170	55
	7.8	95	85
	9.0	100	35
	10.0	135	50
	10.2	180	50
	10.6	165	70
	10.6	145	65
	10.8	160	45
	11.0	105	55
	11.6	105	25
	12.0	165	25
	12.8	90	50
	13.6	75	25
Avg		129	52
Abnormal activity	14.2	85	30
	14.8	165	40
	16.2	310	75
	16.2	125	25
	17.2	150	35
	17.8	70	40
	18.0	50	20
	19.0	55	20
	19.6	125	25
Avg		126	34.4

sented here have been obtained by Chargaff (13). He showed a relation between clotting times of chicken plasma and the concentration of phospholipid obtained from platelets. Marcus *et al.*(7,8) and others(13) observed that phospholipids isolated from platelets could be substituted for platelets in the thromboplastin generation tests. Therefore,

TABLE III. Phospholipid Contained when Acid Buffer Used.

Thromboplastin activity in sec.		μg total lipid phosphorus/3 ml thromboplastin
Before washing	After washing	
15.4	20.6	120
18.4	21.0	175
22.8	21.8	227
22.0	21.8	235
21.2	22.4	80
15.0	27.0	80
23.6	32.8	60
28.2	56.2	130
48.6	57.6	90
37.0	61.0	110
35.0	80.0	85
24.0	96.0	75

it is conceivable that the relation between total phospholipids and blood thromboplastin clotting times obtained in this investigation may merely represent an artifact of centrifugation of platelets and their phospholipid material into the thromboplastin matrix.

We do not think that this is true for several reasons. First, as shown in Table I, total phospholipid content of the preincubation mixture is much greater than that found in the formed thromboplastin matrix. Also, as shown in Table II, there is no correlation between phospholipid content of the centrifugation product containing the precursor substances and thromboplastic activity or total phospholipid content of the thromboplastin. Thus, the phospholipid of the formed thromboplastin is apparently not related simply to centrifugation of platelets and phospholipid micelles.

The amount of phospholipid found in the blood thromboplastin is directly related to clotting activity of the thromboplastin, as the most active thromboplastins (*i.e.*, those with the shortest clotting time) have the greatest amounts of phospholipid. There seems to be a correlation here between loss of activity and loss of total phospholipid. However, adequate amounts of phospholipid alone do not mean that strong thromboplastic activity will be present. As shown in Table III, if initial adequate thromboplastic activity is never attained because of low pH, the amount of sedimented phospholipid is very high despite low blood thromboplastin activity. Apparently, either a certain order of linkage, certain phospholipids or the proper ratios of phospholipids must be incorporated into blood thromboplastin during generation to obtain activity. This strongly suggests that active chemical changes occur during blood thromboplastin formation. We interpret this evidence to indicate that phospholipids play an

essential role in blood thromboplastin activity. The relation between amount of thromboplastin activity and phospholipid content is compatible with this concept.

Summary. (1) The amount of total phospholipid in blood thromboplastin was found to correlate with thromboplastic activity. (2) A sufficient concentration of the total phospholipid in formed thromboplastin appears to be critical. However, the mere presence of phospholipid does not insure strong thromboplastic activity. (3) There was no relation between amount of total phospholipid in the precursor substances, either before or after centrifugation, and total phospholipid in the blood thromboplastin. This strongly suggests that active changes occur during thromboplastin formation.

1. Troup, S. B., Reed, C. F., Marinetti, G. V., Swisher, S. N., *J. Clin. Invest.*, 1960, v39, 342.
2. Barkhan, P., Silver, M. J., *Blood*, 1960, v15, 428. (Abst.).
3. Therriault, D., Nichols, T., Jensen, H., *J. Biol. Chem.*, 1958, v233, 1061.
4. Wallach, D. F. H., Maurice, P. A., Steele, B. B., Surgenor, D. M., *ibid.*, 1959, v234, 2829.
5. Rouser, G., White, S. G., Schloredt, D., *Biochim. et Biophys. Acta*, 1958, v28, 71.
6. Rouser, G., Schloredt, D., *ibid.*, 1958, v28, 81.
7. Marcus, A. J., Spaet, T. H., *J. Clin. Invest.*, 1958, v37, 1836.
8. Marcus, A. J., Ullman, H. L., Walfman, M., *J. Lipid Res.*, 1960, v1, 179.
9. Horowitz, H. I., Spaet, T. H., *J. Applied Physiol.*, 1961, v16, 112.
10. Spaet, T. H., Cintron, J., *Proc. Soc. Exp. Biol. and Med.*, 1959, v101, 799.
11. Marinetti, G. V., Albrecht, M., Ford, T., Stotz, E., *Biochim. et Biophys. Acta*, 1959, v36, 4.
12. Marinetti, G. V., Erbland, J., Kechen, J., *Fed. Proc.* 1957, v16, 837.
13. Chargaff, E., *J. Biol. Chem.*, 1944, v155, 387.

Received September 29, 1961. P.S.E.B.M., 1962, v109.